![\"A](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/10\/1760717528_785_image002.jpg\")
<\/p>\nImplantable Medical Devices Market
\nSegmentation Analysis:<\/b><\/p>\n
By Product Analysis:<\/b><\/p>\n
The cardiovascular implants segment
\ndominates in the implantable medical devices market, as these types of implants
\nfind broad medical healthcare applications, making an excessive contribution to
\nthe management of cardiovascular diseases. Increasing incidence of chronic and
\ncardiovascular diseases (CVDs), and technological advancement, with limited
\nbiological replacement options available. These devices are related to lawful
\nimplications, including malpractice lawsuits associated with negligence and
\nproduct liability. It supports the heart in maintaining a steady and steady
\nheart rhythm and flow of blood in the body.<\/p>\n
On the other hand, the dental implants
\nsegment is expected to grow significantly during the forecast period, as they
\nare permanently attached to the jaw, and they offer enhanced oral comfort
\ncompared to dentures, which slip and move in the mouth. Dental implants offer a
\nnatural-feeling and natural-looking replacement for a lost tooth that lasts for
\nmany years. It supports preserving speech patterns by filling holes in teeth
\nthat cause variations in the way air passes by the mouth when talking.<\/p>\n
By Biomaterial Analysis:<\/b><\/p>\n
The metallic segment dominated the market
\nin 2024, as this type of implant is the primary biomaterial used for joint
\nreplacement and is becoming progressively important. The metallic implants used
\nfor orthopedic applications are categorized as CoCr alloys, stainless steel,
\nand Ti and Ti alloys. These metallic materials have numerous characteristics
\nsuch as high strength, high fracture toughness, corrosion resistance, hardness,
\nand biocompatibility, which make them an outstanding choice for entire joint
\nreplacement.<\/p>\n
On the other hand, the natural segment is
\nexpected to grow at the fastest CAGR in the market during the forecast period,
\nas it provides advantages such as a natural entrance and durability, feel,
\nenhanced function, and chronic oral health advantages. They are attached to the
\njawbone, offering stability for eating and speaking, and last a lifetime with
\nappropriate care. Implants are intended to look, function, and feel such as
\nnatural teeth, supporting to restoration of confidence.<\/p>\n
By End Use Analysis:<\/b><\/p>\n
The hospitals segment dominated the market
\nin 2024, as these implants are used to replace body parts such as hips or
\nknees, deliver medication such as for pain relief, monitor and regulate body
\nfunctions such as heart rate, and provide support to organs and tissues. Some
\nimplants are inert and intended to provide structural support, such as medical
\nstents or meshes.<\/p>\n
<\/p>\n
On the other hand, the outpatient
\nfacilities segment is expected to grow at the fastest CAGR in the market during
\nthe forecast period, as the most significant advantages of outpatient joint
\nreplacement are the improved recovery time compared to outdated inpatient
\nsurgeries. Outpatient processes often use Enhanced Recovery After Surgery
\n(ERAS) protocols, which focus on lowering the body\u2019s strain response to
\nsurgery. Outpatient joint replacement predominantly lowers the economic burden
\non patients and the medical care system.<\/p>\n
By Regional Insight<\/b><\/p>\n
North America dominated the implantable
\nmedical devices market in 2024, due to its strong and well-developed medical
\ncare infrastructure, including leading specialized treatment centers and
\nhospitals. These services are equipped with modern technology for multifaceted
\nclinical procedures and medical care. Increasing incidence of chronic diseases,
\nsuch as cardiovascular and nervous system disorders, which are major driver of
\ndemand for implants such as neurostimulators, stents, and pacemakers.<\/p>\n
\ud83d\udd39<\/b>For Instance, In July 2025, Inari Medical, now part of Stryker, a
\nglobal leader in medical technologies, announced the launch of its
\nnext-generation InThrill Thrombectomy System, the first and only purpose-built
\nsmall vessel and arteriovenous (AV) access thrombectomy system that can deliver
\nfast, full luminal clot removal.\u00a0 <\/p>\n
In the U.S. growing aging population is
\nmore prone to age-associated health conditions, such as joint degeneration and
\ncardiovascular issues, further driving the requirement for implantable devices.
\nA rising preference for less invasive surgical procedures increases demand for
\nprogressive implantable devices that provide rapid recovery times and lower
\ncomplications.<\/p>\n
\ud83d\udd39<\/b>For Instance, In March 2025, Boston Scientific Corporation announced
\nentered into a definitive agreement to acquire SoniVie Ltd., a privately held
\nmedical device company that has developed the TIVUS Intravascular Ultrasound
\nSystem. An investigational technology, the TIVUS system is designed to
\ndenervate nerves surrounding blood vessels to treat a variety of hypertensive
\ndisorders, including renal artery denervation (RDN) for hypertension.<\/p>\n
Why is Asia Pacific the Fastest Growing
\nin the Implantable Medical Devices Market?<\/b><\/p>\n
APAC is the fastest-growing region in the
\nmarket, as the growing burden of chronic conditions like CVD disease, diabetes,
\nand cancer is increasing in the region, driven by urbanization and lifestyle
\nvariations. This increases demand for healthcare technologies such as
\northopedic implants and cardiac stents. The acceptance of technologies like
\nartificial intelligence (AI), 3D printing, and smart implants is fast-tracking
\nin the region. Increasing government support in countries like India and China
\nis implementing favorable policies, including investment incentives for local
\nmanufacturers, to lower import dependency and improve affordability.<\/p>\n
\ud83d\udd39<\/b>For Instance, In November 2024, the Indian government\u2019s newly
\nlaunched Rs 500 crore MedTech scheme is expected to revitalise domestic
\nmanufacturing within the medical equipment sector, which has largely shifted
\ntowards importing and pseudo-manufacturing. The scheme, announced, seeks to
\nenable Indian manufacturers to become global exporters of medical devices and
\nrespond to industry challenges, including skill shortages.<\/p>\n
Implantable Medical Devices Market
\nCompanies:<\/b><\/p>\n
\u2022 Abbott Laboratories<\/p>\n
\u2022 Biotronik SE and Co. KG<\/p>\n
\u2022 Boston Scientific Corporation<\/p>\n
\u2022 Cochlear Limited<\/p>\n
\u2022 Institut Straumann AG<\/p>\n
\u2022 Integra LifeSciences Corporation<\/p>\n
\u2022 Johnson and Johnson<\/p>\n
\u2022 LivaNova PLC<\/p>\n
\u2022 Medtronic<\/p>\n
\u2022 Smith & Nephew plc<\/p>\n
\u2022 Stryker<\/p>\n
What is Going Around the Globe?<\/b><\/p>\n
\u2b25\ufe0e<\/b>In October 2025, Medtronic plc.
\nannounced the start of the Embrace Gynecology investigational device exemption
\n(IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo
\nrobotic-assisted surgery (RAS) system in robotic-assisted gynecological
\nprocedures.<\/p>\n
\u2b25\ufe0e<\/b>In September 2025, Medtronic plc, a
\nglobal leader in healthcare technology, announced that it had received U.S.
\nFood and Drug Administration (FDA) approval for the Altaviva device. The
\nminimally invasive implantable tibial neuromodulation (ITNM) therapy is
\ninserted near the ankle and designed to treat urge urinary incontinence.\u00a0 <\/p>\n
\u2b25\ufe0e<\/b>In September 2025, Biogen Inc.
\nannounced the company had entered into a definitive agreement to acquire
\nMassachusetts-based Alcyone Therapeutics. As part of an existing partnership
\nwith Alcyone Therapeutics, the companies are advancing ThecaFlex DRx, an
\nimplantable subcutaneous port and catheter device being investigated for the
\nintrathecal delivery of antisense oligonucleotides (ASOs). <\/p>\n
\u2b25\ufe0e<\/b>In October 2025, AtaCor Medical, Inc.,
\na privately-held medical device company focused on transforming cardiac rhythm
\nmanagement systems, announced today that it has entered into a financing of up
\nto $75 million. The proceeds will fund the company’s U.S. FDA Pivotal Study
\nevaluating AtaCor’s parasternal extravascular implantable
\ncardioverter-defibrillator (EV-ICD) system for the treatment of life-threatening
\nventricular tachyarrhythmias.<\/p>\n
You can place an order or ask any Related Report \u2013 <\/b><\/p>\n \ud83d\udd39 \ud83d\udd39 \ud83d\udd39 \ud83d\udd39 \ud83d\udd39 \ud83d\udd39 Implantable Medical Devices Market Segments Covered in the Report <\/b><\/p>\n By Product<\/b><\/p>\n \u2022 Aesthetic Implants<\/p>\n \u2022 Cardiovascular Implants<\/p>\n \u2022 Dental Implants<\/p>\n \u2022 Neurology Implants<\/p>\n \u2022 Orthopedic Implants<\/p>\n \u2022 Ophthalmology Implants<\/p>\n By Biomaterial<\/b><\/p>\n \u2022 Ceramic<\/p>\n \u2022 Metallic<\/p>\n \u2022 Natural<\/p>\n \u2022 Polymers<\/p>\n By End Use<\/b><\/p>\n \u2022 Hospitals<\/p>\n \u2022 Outpatient Facilities<\/p>\n \u2022 Specialty Clinics & Centers<\/p>\n By Regional<\/b><\/p>\n \u2022 North America<\/p>\n \u2022 Europe<\/p>\n \u2022 Asia Pacific<\/p>\n \u2022 Latin America<\/p>\n \u2022 Middle East and Africa (MEA)<\/p>\n Immediate Delivery Available | Buy This About-Us<\/b><\/p>\n Nova One Advisor is a global leader Our expertise spans the entire biotech Web: <\/b>https:\/\/www.novaoneadvisor.com\/<\/b><\/a><\/p>\n Contact Us<\/b><\/p>\n USA:<\/b>\u00a0+1 804 420 9370<\/p>\n Email: <\/b>sales@novaoneadvisor.com<\/b><\/a><\/p>\n
\nquestions, please feel free to contact at\u00a0<\/b>sales@novaoneadvisor.com<\/b><\/a> \u00a0|
\n+1 804 441 9344<\/b><\/p>\n
\nHi-Tech Medical Devices Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/hi-tech-medical-devices-market<\/b><\/a>
\n<\/b><\/p>\n
\nNanotechnology in Medical Devices Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/nanotechnology-in-medical-devices-market<\/b><\/a>
\n<\/b><\/p>\n
\nWearable Medical Devices Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/wearable-medical-devices-market<\/b><\/a>
\n<\/b><\/p>\n
\nU.S. Reprocessed Medical Devices Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/us-reprocessed-medical-devices-market<\/b><\/a>
\n<\/b><\/p>\n
\nMedical Devices Vigilance Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/global-medical-devices-vigilance-market<\/b><\/a>
\n<\/b><\/p>\n
\nU.S. Wearable Medical Devices Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/us-wearable-medical-devices-market<\/b><\/a>
\n<\/b><\/p>\n
\nSegmentation:<\/b><\/p>\n
\nPremium Research <\/b>https:\/\/www.novaoneadvisor.com\/report\/checkout\/9181<\/b><\/a>
\n<\/b><\/p>\n
\nin market intelligence and strategic consulting, committed to delivering deep,
\ndata-driven insights that power innovation and transformation across
\nindustries. With a sharp focus on the evolving landscape of life sciences, we
\nspecialize in navigating the complexities of cell and gene therapy, drug
\ndevelopment, and the oncology market, enabling our clients to lead in some of
\nthe most revolutionary and high-impact areas of healthcare.<\/p>\n
\nand pharmaceutical value chain, empowering startups, global enterprises,
\ninvestors, and research institutions that are pioneering the next generation of
\ntherapies in regenerative medicine, oncology, and precision medicine. <\/p>\n